Lineage Cell Therapeutics, Inc.
LCTX
Positions held
Your positionsLCTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $260.49M | Enterprise value | $210.85M | Trailing P/E | — | Forward P/E | -7.49 |
| PEG | 10.64 | Price / book | 4.27 | Beta | 1.60 | Dividend yield | 0.00% |
| Revenue growth | -61.3% | Earnings growth | — | Gross margin | -57.4% | Operating margin | -8.3% |
| Profit margin | -2.5% | ROE | -60.1% | ROA | -17.0% | Debt / equity | 0.04 |
| Current ratio | 6.61 | Free cash flow | -$14.77M | Analyst recommendation | strong_buy | Mean target | $5.50 |
| 52w high | $2.09 | 52w low | $0.88 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $6.6M | $3.7M | $2.8M | — |
| Op margin | -834.7% | -440.2% | -99.1% | -102.9% | -178.7% | — |
| Net income | $1.5M | -$4.8M | $0.9M | -$29.8M | -$30.5M | — |
| Gross margin | 100.0% | 100.0% | 99.0% | 99.9% | 98.6% | — |
| Gross profit | $1.1M | $1.7M | $6.5M | $3.7M | $2.7M | — |
| Operating income | -$8.9M | -$7.6M | -$6.5M | -$3.8M | -$4.9M | — |
- Revenue -38% vs prior quarter ($1.1M vs $1.7M).
- Gross margin 100% (was 100% prior quarter).
- Operating margin compressed to -834.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $14.6M | $9.5M | $8.9M | $14.7M | — |
| Op margin | -149.6% | -226.1% | -276.5% | -153.2% | — |
| Net income | -$63.5M | -$18.6M | -$21.5M | -$26.3M | — |
| Gross margin | 99.0% | 96.5% | 92.5% | 95.0% | — |
| Gross profit | $14.4M | $9.2M | $8.3M | $14.0M | — |
| Operating income | -$21.8M | -$21.5M | -$24.7M | -$22.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-16 · 3 Small Cap Stocks With Strong Revenue Growth And Low Debt
2026-09-08 · Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
2026-08-14 · Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript
2026-08-09 · Lineage Cell Therapeutics Q2 Earnings Call Highlights
2026-08-07 · Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary
2026-08-07 · Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended, ...
2026-08-06 · Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-06 · Lineage Cell: Q2 Earnings Snapshot
2026-08-06 · Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-14 · Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan
2026-07-13 · Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease
Price (daily)
Full chart · RSI · MACD · patterns